Our study agreed with this report, as higher serum IL-13 and polymorphism at STAT6 rs167769 were reported to be the strongest variables associated with cancer progression in NASH patients, regardless of their fibrosis stages. Here, STAT6 is linked to metabolic dysfunction-associated steatohepatitis.